日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Americas

Canada, China team up for vaccine candidate

By RENA LI in Toronto | China Daily Global | Updated: 2020-05-14 11:37
Share
Share - WeChat
Scientists are seen working on a potential vaccine for COVID-19, following the outbreak of the coronavirus disease (COVID-19), in Keele, Britain, April 30, 2020. [Photo/Agencies]

The National Research Council of Canada is collaborating with China's CanSino Biologics Inc to advance the bioprocessing and clinical development in Canada of a vaccine candidate against the novel coronavirus.

The collaboration on the vaccine candidate, Ad5-nCoV, was announced Tuesday. Ad5-nCoV received Chinese regulatory approval earlier this year, allowing CanSinoBIO to move ahead with human clinical trials in China.

It is one of only a handful of COVID-19 vaccine candidates in the world approved for initial safety testing in humans, and was the first to begin conducting phase-two human clinical trials, according to a statement released by the NRC.

"This vaccine candidate holds great promise. Until such time as there is an effective vaccine for COVID-19, the virus will continue to disrupt all aspects of our society and economy," said Iain Stewart, president of the NRC.

The relationship between the NRC and CanSinoBIO was established in 2013. The NRC's HEK293 cell line was later licensed to CanSinoBIO and used in the development of an approved vaccine against the Ebola virus.

Yu Xuefeng, CEO of CanSinoBIO, said it was "perfect timing" to leverage cutting-edge technology and resources from both sides that are critical to the development of Ad5-nCoV.

"We are in this global public health emergency together, and a collaborative engagement could be the shortcut to help win this race against the novel coronavirus," said Yu.

The statement said that the new COVID-19 vaccine is also produced using HEK293 cell lines that were designed and developed at the NRC.

By bringing their technologies and expertise together to fight COVID-19, CanSinoBIO and the NRC are aiming to "pave the way" for future clinical trials in Canada, in collaboration with the Canadian Immunization Research Network at the Canadian Center for Vaccinology.

The vaccine is subject to approval by Health Canada, for which CanSinoBIO is in the process of filing a clinical trial application.

The first- and second-phase human trials have already started in China. Chinese Science and Technology Daily said that the first-phase studies for Ad5-nCoV began in March, with 108 people taking three different doses.

In an unusual step, CanSinoBIO began second-phase testing in early April with 500 people, even though the first phase will not be completed until December. A third phase could involve a far larger number of people, perhaps as many as 10,000.

Lakshmi Krishnan, director general of the NRC's Human Health Therapeutics Research Centre, said the trials in Canada will complement and expand on what's been done in China.

"We're bringing back home a Canadian technology, and we're able to have the most advanced vaccine candidate in the world potentially available for Canadians in short order," Krishnan told CBC News.

She said a phase-one trial for the Ebola vaccine took place at the Canadian Centre for Vaccinology in Halifax. The first coronavirus vaccine also will be tested on healthy human volunteers there.

If successful, the phase-two trials could start in the fall, with a vaccine available for noncommercial use for front-line workers and those at risk in late 2020 or early 2021.

The collaboration announced Tuesday will allow the NRC to advance a scaled-up production process for the vaccine candidate, using its proprietary HEK293 cell line.

As a preparatory step, the Canadian government has already announced $44 million in funding to support upgrades to the NRC's facilities in Montreal to enable compliance with good manufacturing practice standards, to ensure readiness for Canadian bioprocessing of potential vaccine candidates as they become available.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 精品免费久久久久欧美亚一区 | 九月婷婷开心九月 | 日韩精品一区二区电影 | 成在线人视频免费视频 | videos 欧美| 久久一精品 | 亚洲一区二区三区精品视频 | 亚洲欧美一区二区三区久本道 | 人人天天操 | 韩国精品免费视频 | 午夜视频1000 | 98香蕉草草视频在线精品看 | 午夜国产亚洲精品一区 | 噜噜色网| 欧美天天视频 | 青青草在线免费视频 | 日本高清电影在线播放 | 国产综合一区二区 | 国产精品伊人 | 三级国产短视频在线观看 | 91精品国产乱码久久久久久久久 | 成人福利在线视频 | 香蕉久久一区二区不卡无毒影院 | 一区二区日韩 | 国产欧美精品一区二区三区 | 自拍偷拍中文字幕 | 日日麻批 | 国产成人精品福利网站在线观看 | k8久久久一区二区三区 | 亚洲免费一级视频 | 午夜影院毛片 | 日韩一区二区中文字幕 | 国产在线视频一区二区 | 亚洲欧美日韩一区二区在线观看 | 国产精品影视 | 九九视频只有精品六 | 一级毛片免费不卡在线 | 亚洲精品一二三区-久久 | 成人人观看的免费毛片 | 国产精品微拍 | 日本黄色免费片 |